BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Summary by AI BETAClose X

BioNTech reported third quarter 2025 revenues of €1.5 billion, an increase compared to €1.24 billion in the same period of 2024, primarily driven by revenues from the Bristol Myers Squibb partnership. The company experienced a net loss of €28.7 million, or a loss per share of €0.12 ($0.14), compared to a net profit of €198.1 million in Q3 2024. BioNTech's financial position was strengthened by a $1.5 billion payment from the BMS partnership, resulting in €16.7 billion in cash, cash equivalents, and security investments. The company increased its revenue guidance for 2025 to a range of €2.6-2.8 billion and lowered its expense guidance for R&D to €2.0-2.2 billion, for SG&A to €550-650 million, and for capital expenditures to €200-250 million.

Disclaimer*

UK 100

Latest directors dealings